About semaglutid e
GLP-1 receptor agonist
Used for
- Improves blood sugar control in adults with type 2 diabetes.
- Reduces risk of major cardiovascular events in some adults with type 2 diabetes and cardiovascular disease.
Usual adult dose
Injected under the skin once weekly; usually starts at 0.25 mg weekly for four weeks, then increases to 0.5 mg. Further increases may be prescribed.
Common side effects
- Nausea, vomiting, diarrhea, constipation, or abdominal pain
- Reduced appetite
- Injection-site reactions
- Low blood sugar, especially with insulin or sulfonylureas
Important warnings
- Not for type 1 diabetes or diabetic ketoacidosis.
- Avoid with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
- Seek urgent care for severe, persistent abdominal pain, which may indicate pancreatitis.
- Tell clinicians before surgery or anesthesia because stomach emptying may be delayed.
Pregnancy
Generally not recommended during pregnancy; stop at least two months before a planned pregnancy.
Breastfeeding
Discuss use with a clinician; evidence about effects on breastfed infants is limited.
Interactions
- Insulin or sulfonylureas can increase low blood sugar risk.
- Delayed stomach emptying may affect absorption of oral medicines.
- May affect medicines requiring close monitoring, such as warfarin.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.